Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation

BMC Urology

Research Article

Arnulf Stenzl¹  Jörg Hennenlotter¹  Natalie Stickel²  Juliane S Stickel³  Stefan Stevanović³  Hans-Georg Rammensee³  Karin Klingel⁴ 

[1] Clinic for Urology, University of Tübingen, Germany;Department of Hematology Oncology, University of Freiburg, Germany;Department of Immunology, Institute for Cell Biology, University of Tübingen, Germany;Department of Molecular Pathology, University of Tübingen, Germany;

关键词: Renal Cell Carcinoma;    Metastatic Renal Cell Carcinoma;    Tumor Infiltrate Lymphocyte;    Renal Cell Carcinoma Patient;    Edman Degradation;   

DOI  :  10.1186/1471-2490-11-1

 received in 2010-09-11, accepted in 2011-01-20,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundUnimpaired HLA class I antigen presentation is a prerequisite for the recognition of tumor cells by cytotoxic T lymphocytes and thus essential for the success of anticancer immunotherapeutic concepts. Several approaches have been taken in the immunotherapy of metastatic renal cell carcinoma (RCC), however of limited success. HLA loss or down-regulation have often been reported and might interfere with immunotherapeutic approaches aimed at the recognition of HLA-presented peptides.MethodsWe employed a quantitative method of molecular analysis for the comparison of HLA amounts on primary tumor, normal kidney and metastases of RCC, using Edman degradation. We analyzed a series of 47 RCC samples including corresponding renal parenchyma, local lymph node metastases and distant metastases.ResultsResults of quantitative Edman degradation revealed significantly higher HLA yields on primary tumor and metastases compared to normal kidney tissue. This effect was shown not to result from infiltrating immune cells, since tumor-infiltrating lymphocytes had no influence on the overall HLA recovery from tumor tissue. Unexpectedly, we found a higher amount of HLA class I molecules on distant metastases compared to local lymph node metastases.ConclusionEdman degradation allows the direct quantitative comparison of HLA class I protein expression by tumor or normal tissue and metastases of RCC patients. Our results raise hopes for improving the success and effectiveness of future immunotherapeutic concepts for metastatic RCC.

【 授权许可】

Unknown   
© Stickel et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.